CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation Prdm16 Deficiency Leads to Age-Dependent Cardiac Hypertrophy, Adverse Remodeling, Mitochondrial Dysfunction, and Heart Failure Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk Factors Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction" Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes
|<<... 9 10 11 12 13 14 15 ...>>|

Original Research2019 May;21(5):665-675.

JOURNAL：Eur J Heart Fail. Article Link

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators. Keywords: protocol; heart failure; sodium-glucose co-transporter 2 inhibitor; type 2 diabetes mellitus

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top